risk.
Grade
Best Practice Statement

Certainty of evidence

1124

Journal of Vascular Surgery

Fitridge et al

November 2023

Recommendation 25
In a person with type 2 diabetes and peripheral artery disease:

with an eGFR > 30 mL/min/1.73m2, a sodium glucose
cotransporter-2 (SGLT-2) inhibitor or a glucagon like
peptide